January 2013 | Targeted Therapies in Oncology

Biomarker May Predict Response to Bevacizumab in mCRC

February 21, 2013

Clinical Articles

Researchers have identified a potential predictive marker for survival in cases of mCRC treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug.

Enzalutamide Delays First SRE, Improves Pain and QoL in Patients With Metastatic Prostate Cancer

February 13, 2013

Clinical Articles

An analysis of the phase III AFFIRM trial showed that enzalutamide significantly delayed the time to first skeletal-related event and significantly improved pain and quality of life compared with placebo in men with mCRPC who had received prior docetaxel.